Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Gynecologic 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 485Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sequence Analysis, RNA × Breast × Clear all
NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Fudan University

Phase 2 Unknown
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03521245 2021-09-14

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

OmicsWay Corp.

Unknown
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡